


Product Name : Ponatinib
Cat. No. : PC-42862
CAS No. : 943319-70-8
Molecular Formula : C₂₉H₂₇F₃N₆O
Molecular Weight : 532.5595
Target : Bcr-Abl
Solubility : DMSO: ≥ 50 mg/mL



Biological Activity

Ponatinib (AP 24534) is a potent, orally active pan-inhibitor of BCR-ABL kinase with IC₅₀ of 0.37 and 2.0 nM for ABL and mutant ABLT315I, respectively; retains high potency against other ABL mutants Q252H, Y253F, M351T and H396P (IC₅₀s < 0.5 nM), also inhibits c-Src, Lyn, c-KIT, VEGFR2, FGFR1, PDGFRα (IC₅₀s = 0.2-5 nM); inhibits the growth of cells expressing native or mutant BCR-ABL (IC₅₀s = 0.5-36 nM) suppresses BCR-ABL(T315I)-driven tumor growth in mice, and completely abrogated resistance in cell-based mutagenesis screens.

Blood Cancer

Approved

References

Gozgit JM, et al. Mol Cancer Ther. 2011 Jun;10(6):1028-35.

Huang WS, et al. J Med Chem. 2010 Jun 24;53(12):4701-19.

O'Hare T, et al. Cancer Cell. 2009 Nov 6;16(5):401-12.

Gozgit JM, et al. Mol Cancer Ther. 2012 Mar;11(3):690-9.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com